Evidence map›Paper›PMID 35625388›Full record

ArticleBiology2022

Reduced Segmentation of Lesions Is Comparable to Whole-Body Segmentation for Response Assessment by PSMA PET/CT: Initial Experience with the Keyhole Approach.

Philipp E Hartrampf, Markus Krebs, Lea Peter, Marieke Heinrich, Julia Ruffing, Charis Kalogirou, Maximilian Weinke, Joachim Brumberg, Hubert Kübler, Andreas K Buck and 2 more

Abstract read
In one paragraph

Article in Biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Early biochemical and radiographic response after one cycle of [European journal of nuclear medicine and molecular imaging · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Philipp E HartrampfDepartment of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, Germany.ORCID 0000-0001-5622-9849
Markus KrebsDepartment of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
Lea PeterDepartment of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
Marieke HeinrichDepartment of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, Germany.
Julia RuffingDepartment of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
Charis KalogirouDepartment of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
Maximilian WeinkeDepartment of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
Joachim BrumbergDepartment of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, Germany.
Hubert KüblerDepartment of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.
Andreas K BuckDepartment of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, Germany.
Rudolf A WernerDepartment of Nuclear Medicine, University Hospital Würzburg, 97080 Würzburg, Germany.
Anna Katharina SeitzDepartment of Urology and Pediatric Urology, University Hospital Würzburg, 97080 Würzburg, Germany.

Funding

IZKF Würzburg Z-02/85
6 · The paper itself

Abstract

(1) Background: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)-derived parameters, such as the commonly used standardized uptake value (SUV) and PSMA-positive tumor volume (PSMA-TV), have been proposed for response assessment in metastatic prostate cancer (PCa) patients. However, the calculation of whole-body PSMA-TV remains a time-consuming procedure. We hypothesized that it may be possible to quantify changes in PSMA-TV by considering only a limited number of representative lesions. (2) Methods: Sixty-five patients classified into different disease stages were assessed by PSMA PET/CT for staging and restaging after therapy. Whole-body PSMA-TV and whole-body SUV

Indexed as

PET/CTprostate cancerPSMA-TVradioligand therapySUVtaxane

Identifiers

PMID35625388
PMCPMC9137844

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.